These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29479841)

  • 1. Glioblastoma-activated pericytes support tumor growth via immunosuppression.
    Sena IFG; Paiva AE; Prazeres PHDM; Azevedo PO; Lousado L; Bhutia SK; Salmina AB; Mintz A; Birbrair A
    Cancer Med; 2018 Apr; 7(4):1232-1239. PubMed ID: 29479841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pericytes Are Immunoregulatory Cells in Glioma Genesis and Progression.
    Martinez-Morga M; Garrigos D; Rodriguez-Montero E; Pombero A; Garcia-Lopez R; Martinez S
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.
    Guerra DAP; Paiva AE; Sena IFG; Azevedo PO; Silva WN; Mintz A; Birbrair A
    Angiogenesis; 2018 Nov; 21(4):667-675. PubMed ID: 29761249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma.
    Mohme M; Maire CL; Geumann U; Schliffke S; Dührsen L; Fita K; Akyüz N; Binder M; Westphal M; Guenther C; Lamszus K; Hermann FG; Schmidt NO
    Clin Cancer Res; 2020 Jun; 26(11):2626-2639. PubMed ID: 31988196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.
    Amin T; Hossain A; Jerin N; Mahmud I; Rahman MA; Rafiqul Islam SM; Islam SMBU
    Cancer Control; 2024; 31():10732748241290067. PubMed ID: 39353594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
    Liu Y; Song C; Shen F; Zhang J; Song SW
    PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioma-associated cancer-initiating cells induce immunosuppression.
    Wei J; Barr J; Kong LY; Wang Y; Wu A; Sharma AK; Gumin J; Henry V; Colman H; Sawaya R; Lang FF; Heimberger AB
    Clin Cancer Res; 2010 Jan; 16(2):461-73. PubMed ID: 20068105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Interplay between Glioblastoma and Its Microenvironment.
    Dapash M; Hou D; Castro B; Lee-Chang C; Lesniak MS
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?
    Cui X; Wang Q; Kang C
    Front Immunol; 2021; 12():788733. PubMed ID: 34777399
    [No Abstract]   [Full Text] [Related]  

  • 16. The Dynamics of Interactions Among Immune and Glioblastoma Cells.
    Eder K; Kalman B
    Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the immune system in glioblastoma.
    Brown NF; Carter TJ; Ottaviani D; Mulholland P
    Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.
    Ma J; Chen CC; Li M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of IL-17 in the pathogenesis and treatment of glioblastoma-an update on the state of the art and future perspectives.
    Łaszczych D; Czernicka A; Gostomczyk K; Szylberg Ł; Borowczak J
    Med Oncol; 2024 Jun; 41(8):187. PubMed ID: 38918274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches.
    Sarkar S; Patranabis S
    Hum Cell; 2024 Sep; 37(5):1355-1377. PubMed ID: 39085713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.